Celgene CVR (CELGZ)

[roadkilll]

Why is this CVR so cheap?

The reasoning behind these value opportunities is largely a result of the fact that many of the institutional shareholders are forced to sell these securities because they do not fit their mandate, and many shareholders (both institutional and otherwise) sell because they are perceived to add little value relative to the amount of work that must go into understanding them.

http://www.frankvoisin.com/2010/12/21/celgene-corp-celg-contingent-value-rights/

Impressive ESMO tweeting about Abraxane and how the oncologist are expecting news sooner than expected. Early halt to trial due to humanitarian access as the control arm matures quickly? Remember that many of the oncologists that are impressed with Abraxane are able to use it off label, with the NCCN rating 2b you get third party coverage. No doubt the doctors using it off label know how well it works for these patients.
Again, why cheap? Nobody is allowed to publish off label results and trumpet the cause, FDA regulations.